Wawer M J, Sewankambo N K, Serwadda D, Quinn T C, Paxton L A, Kiwanuka N, Wabwire-Mangen F, Li C, Lutalo T, Nalugoda F, Gaydos C A, Moulton L H, Meehan M O, Ahmed S, Gray R H
Centre for Population and Family Health, Columbia University School of Public Health, New York 10032, USA.
Lancet. 1999 Feb 13;353(9152):525-35. doi: 10.1016/s0140-6736(98)06439-3.
The study tested the hypothesis that community-level control of sexually transmitted disease (STD) would result in lower incidence of HIV-1 infection in comparison with control communities.
This randomised, controlled, single-masked, community-based trial of intensive STD control, via home-based mass antibiotic treatment, took place in Rakai District, Uganda. Ten community clusters were randomly assigned to intervention or control groups. All consenting residents aged 15-59 years were enrolled; visited in the home every 10 months; interviewed; asked to provide biological samples for assessment of HIV-1 infection and STDs; and were provided with mass treatment (azithromycin, ciprofloxacin, metronidazole in the intervention group, vitamins/anthelmintic drug in the control). Intention-to-treat analyses used multivariate, paired, cluster-adjusted rate ratios.
The baseline prevalence of HIV-1 infection was 15.9%. 6602 HIV-1-negative individuals were enrolled in the intervention group and 6124 in the control group. 75.0% of intervention-group and 72.6% of control-group participants provided at least one follow-up sample for HIV-1 testing. At enrolment, the two treatment groups were similar in STD prevalence rates. At 20-month follow-up, the prevalences of syphilis (352/6238 [5.6%]) vs 359/5284 [6.8%]; rate ratio 0.80 [95% CI 0.71-0.89]) and trichomoniasis (182/1968 [9.3%] vs 261/1815 [14.4%]; rate ratio 0.59 [0.38-0.91]) were significantly lower in the intervention group than in the control group. The incidence of HIV-1 infection was 1.5 per 100 person-years in both groups (rate ratio 0.97 [0.81-1.16]). In pregnant women, the follow-up prevalences of trichomoniasis, bacterial vaginosis, gonorrhoea, and chlamydia infection were significantly lower in the intervention group than in the control group. No effect of the intervention on incidence of HIV-1 infection was observed in pregnant women or in stratified analyses.
We observed no effect of the STD intervention on the incidence of HIV-1 infection. In the Rakai population, a substantial proportion of HIV-1 acquisition appears to occur independently of treatable STD cofactors.
本研究检验了这样一个假设,即与对照社区相比,社区层面的性传播疾病(STD)控制将导致HIV-1感染发病率降低。
这项通过家庭大规模抗生素治疗进行强化STD控制的随机、对照、单盲社区试验在乌干达的拉凯区开展。10个社区集群被随机分配到干预组或对照组。所有年龄在15至59岁且同意参与的居民均被纳入;每10个月进行一次家访;进行访谈;要求提供生物样本以评估HIV-1感染和STD情况;并为干预组提供大规模治疗(阿奇霉素、环丙沙星、甲硝唑),为对照组提供维生素/驱虫药。意向性分析采用多变量、配对、集群调整率比。
HIV-1感染的基线患病率为15.9%。干预组纳入6602名HIV-1阴性个体,对照组纳入6124名。干预组75.0%的参与者和对照组72.6%的参与者至少提供了一份用于HIV-1检测的随访样本。在入组时,两个治疗组的STD患病率相似。在20个月的随访中,干预组梅毒患病率(352/6238 [5.6%])低于对照组(359/5284 [6.8%]);率比为0.80 [95%置信区间0.71 - 0.89]),滴虫病患病率(182/1968 [9.3%] 对比261/1815 [14.4%];率比为0.59 [0.38 - 0.91])也显著低于对照组。两组HIV-1感染发病率均为每100人年1.5例(率比0.97 [0.81 - 1.16])。在孕妇中,干预组滴虫病、细菌性阴道病、淋病和衣原体感染的随访患病率显著低于对照组。在孕妇或分层分析中未观察到干预对HIV-1感染发病率的影响。
我们未观察到STD干预对HIV-1感染发病率有影响。在拉凯人群中,相当一部分HIV-1感染似乎独立于可治疗的STD协同因素发生。